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Background: Infantile Pompe disease is a rare metabolic disease. Patients generally do not survive the first year of
life. Enzyme replacement therapy (ERT) has proven to have substantial effects on survival in infantile Pompe disease.
However, the costs of therapy are very high. In this paper, we assess the cost-effectiveness of enzyme replacement
therapy in infantile Pompe disease.
Methods: A patient simulation model was used to compare costs and effects of ERT with costs of effects of
supportive therapy (ST). The model was filled with data on survival, quality of life and costs. For both arms of the
model, data on survival were obtained from international literature. In addition, survival as observed among 20
classic-infantile Dutch patients, who all received ERT, was used. Quality of life was measured using the EQ-5D and
assumed to be the same in both treatment groups. Costs included the costs of ERT (which depend on a child’s
weight), infusions, costs of other health care utilization, and informal care. A lifetime time horizon was used, with
6-month time cycles.
Results: Life expectancy was significantly longer in the ERT group than in the ST group. On average, ST receiving
patients were modelled not to survive the first half year of life; whereas the life expectancy in the ERT patients was
modelled to be almost 14 years. Lifetime incremental QALYs were 6.8. Incremental costs were estimated to be € 7.0
million, which primarily consisted of treatment costs (95%). The incremental costs per QALY were estimated to be
€ 1.0 million (range sensitivity analyses: € 0.3 million - € 1.3 million). The incremental cost per life year gained was
estimated to be € 0.5 million.
Conclusions: The incremental costs per QALY ratio is far above the conventional threshold values. Results from
univariate and probabilistic sensitivity analyses showed the robustness of the results.
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Since the introduction of orphan drug regulations, the
number of orphan drugs (i.e. drugs for rare diseases) has
grown vastly. This confronts policy makers with a trade-
off between access and affordability. On the one hand,
the overall proportion of orphan drugs in health care ex-
penditures is substantial and continues to grow [1]. On* Correspondence: kanters@bmg.eur.nl
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unless otherwise stated.the other hand, healthcare authorities would like to pro-
vide rapid access to promising new treatments, even when
the evidence base might not be mature yet. To deal with
this trade-off, policy makers can turn to ‘coverage with
evidence development schemes’, which enable patients to
obtain access to the treatment while effectiveness is simul-
taneously studied in a real-world setting [2,3]. When a
cost-effectiveness analysis is performed at the same time,
policy makers also gain insight in the economic conse-
quences of the new treatment. In 2006, such a scheme
was installed in the Netherlands for high-priced in-
hospital orphan drugs. During a coverage with evidenceLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,







N 18 21 20
Deaths 5 (28%) 6 (29%) 4 (20%)
Age at end study in
months [range]
34.5 [19.7-44.0] 41.0 [7.7-80.3] 60.9 [3.2-178.8]
Patients using
ventilation
9 (50%) 7 (33%) 5 (25%)b
Dosage (every other
week)
15 mg/kg 0 0 2c, d
20 mg/kg 9 21a 8e
40 mg/kg 9 0 10d
aEight patients switched to 40 mg/kg after 26 weeks due to clinical
deterioration; bTwo patients died; cBoth patients switched to 30 mg/kg and
later to 40 mg/kg; dEvery week; eFive patients switched to 40 mg/kg.
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effectiveness were studied for orphan drugs listed on a
specific policy rule [4].
One of the drugs reimbursed through this policy rule is a
drug to treat Pompe disease. Pompe disease is a rare meta-
bolic disease and presents as a broad clinical spectrum,
with the rapidly progressive classic-infantile form at the
most severe end and late-onset or adult-onset Pompe dis-
ease at the least severe end [5,6]. In all cases, the disease is
caused by a deficiency of the enzyme acid α-glucosidase.
The incidence of classic-infantile Pompe disease is 1 in
138,000 births [7]. In classic-infantile Pompe disease,
symptoms present in the first months of life and involve re-
spiratory and feeding problems, airway infections, and gen-
eralized muscle weakness. Patients also show progressive
thickening of the heart (hypertrophic cardiomyopathy)
which eventually leads to heart failure. These children gen-
erally die before the first year of age from cardiorespiratory
failure and the median age of death has been estimated to
be 6 to 9 months [8,9].
Enzyme replacement therapy (ERT) with alglucosidase
alfa (Myozyme®, Genzyme corp.) was developed as a treat-
ment for Pompe disease. ERT has proven to have a
substantial effect on survival in classic-infantile Pompe pa-
tients, reducing the 3-year mortality risk by 95% compared
to an untreated historical control group [10,11]. Cardiac,
respiratory and motor functions of patients have been
shown to improve by therapy.
Orphan drugs are often very expensive and this is also
true for ERT to treat Pompe disease [12]. As of 2006,
ERT for Pompe disease is reimbursed in the Netherlands
under a coverage with evidence development scheme, dur-
ing which the cost-effectiveness of the treatment needs to
be assessed, even though this was expected to be unfavor-
able upfront. This study reports on the cost-effectiveness
of ERT in classic-infantile Pompe disease.
Methods
Patients and treatments
All Dutch patients with classic-infantile Pompe disease
were enrolled in an observational study. Diagnosis of
Pompe disease was confirmed by enzyme assay in leuko-
cytes or fibroblasts and/or mutation analysis. All patients
were treated by the Erasmus MC Center for Lysosomal
and Metabolic Diseases, Rotterdam, the Netherlands. The
Institutional Review Board approved the studies. Written
informed consent was provided by parents.
Currently ERT is the only available registered treat-
ment for Pompe disease. In this study, the comparative
treatment therefore consisted of usual supportive therapy
(ST), including for example (nightly) ventilation, surgical
correction of scoliosis, or nutritional support.
The registered dose of ERT is 20 mg/kg/2 weeks. Pa-
tients in the Netherlands received doses ranging from20 mg/kg/2 weeks to 40 mg/kg/week. Since 2008 the
majority of patients use the higher dose. The majority of
the Dutch data was collected in patients using this dose.
In the base case analyses of the model we therefore used
the maximum dose of 40 mg/kg/week.
Study design and model structure
A patient simulation model was used to compare costs
and effects of ERT with costs and effects of ST for pa-
tients with classic-infantile Pompe disease. The model
was filled with data on survival, utilities and costs. For
both treatment arms, the model generated costs, survival,
quality of life and quality adjusted life years (QALYs). In
addition, the model generated an estimate of the cost-
effectiveness of treatment, expressed as cost per QALY.
Effects
Survival
Survival for the ST cohort was retrieved from two inter-
national studies on the natural course of infantile Pompe
disease (n = 172; maximum 24 months follow-up [9] and
119 cases from literature [8]). Survival for the ERT cohort
was obtained from three sources to increase sample size,
i.e. a trial extension study (n = 18; maximum 36 months
follow-up) [11], an international open-label study (n = 21;
median follow-up 28 months) [13] and data from Dutch
infantile patients under treatment at Erasmus MC (n = 20;
median follow-up 32 months). For all cohorts, patient-
level data was available to include in the survival analysis.
Table 1 provides characteristics of the patients in the three
cohorts; the proportion of patients that died and used
ventilation differed between cohorts, as did the dosage
regimens. To extrapolate survival beyond the observed
period, parametric survival models were fitted. Several
distributions were investigated (exponential, Weibull,
Table 2 Cost components and associated unit costs (2009
prices)
Cost component Cost per unitb Source
Hospital day
Regular ward € 394a [18]
Intensive care € 1,847 [18]
Ambulatory care
Hospital day visits € 69a [18]
General practitioner visit € 22 [18]
Physiotherapy € 25 [18]
Other paramedical € 14 - € 91 [18]
Home care per hour € 29 - € 65 [18]
Medication [20]
Other medical costs
Tests & procedures € 54 - € 181 [18]
Respiratory support per day € 5 [21]
Medical devices € 18 - € 1,500 Market prices
Informal care costs per hour € 9 [18]
aweighted average of academic and general hospital costs bcosts per unit are
based on average unit costs for medical procedures, consultations and
admissions [18].
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was based on visual inspection and fit of the model to
the data according to Akaike Information Criterion
(AIC) and Bayesian Information Criterion BIC) [14]. When
predicted survival was higher than in the general popula-
tion, we have applied the mortality rates of the Dutch
population [15].
Quality of life
Quality of life was assessed in Dutch patients using the
Euroqol-5D (EQ-5D), completed by parents of patients
every six months. The EQ-5D is a validated instrument
for measuring and valuing generic health related quality
of life [16]. The instrument describes 245 health states,
and each health state is associated with a utility using a
scoring formula. Utility scores typically range from zero
(death) to 1 (perfect health). Utility scores were estimated
using the Dutch tariff [17]. Only observations for patients
above the age of two years were included (n = 6; median
follow-up 24 months). The average utility was 0.62, ran-
ging from 0.24 to 0.82. For five patients, multiple obser-
vations were available; their average utility was used in
the analyses.
Costs
Costs were calculated from a societal perspective. This
implies that all costs are included, no matter to whom
they accrue. Total costs for patients treated with ERT
consisted of four components: the cost of the drug alglu-
cosidase alfa, infusion-related costs, costs related to other
health care use and informal care costs. Patients receiving
ST did not incur costs of the drug and infusion-related
costs. Costs were expressed in 2009 euro values.
Treatment costs
Costs of the drug alglucosidase alfa are dependent on pa-
tient’s weight. In the Netherlands, costs per vial (50 mg)
are €556.50. In the Netherlands the doses applied in
infants with classic-infantile Pompe disease range from
20 mg/kg/2 weeks to 40 mg/kg/week bodyweight (since
2008 the majority of patients use the higher dose). For the
model we used the maximum dose of 40 mg/kg/week so
drug costs per kilo bodyweight were €445.20. With weekly
infusions (52 infusions per year), yearly medication costs
per kilo are €445.20*52 = €23,150.40. Data from the Dutch
cohort were collected between May 2007 and October
2012. Patients’ weights were estimated on the basis of
available data on Dutch patients (n = 17; median follow-up
35 months), and increased with the patient’s age to a max-
imum of 75 kilograms.
Infusion-related costs were based on detailed time stud-
ies using the methodology described in the Dutch costing
manual [18]. The total costs for infusion consisted of cost
associated to physician and nursing time during infusion,overhead, capital, materials, informal care and travel time.
A distinction was made with respect to treatment location
of patients; patients receive infusions at home or in
hospital. The estimated mean cost per infusion at home
was € 426 compared to € 520 per infusion at the hospital.
A total percentage of 68% of the Dutch patients were
treated in the home situation. Based on weekly infusions
(52 infusions per year), the annual infusion costs were es-
timated to be € 23.710.Other costs
Data of other health care utilization were collected by
means of a health economic questionnaire, completed by
the parents of the Dutch patients (n = 12; median follow-
up 11 months). Bottom-up methodology was used to cal-
culate the total direct medical costs; that is, the total num-
ber of physician and other caregiver contacts multiplied
by unit costs of the corresponding health care services.
Reference unit prices of health care services from the
Dutch costing manual [18] were applied. Costs of informal
care were valued using the shadow price method, also fol-
lowing the costing manual. The estimation of health care
costs was described in more detail for adult non-treated
patients [19]; for infantile patients the same methodology
was used. Table 2 provides the unit costs used. Due to
their age, infantile patients did not incur indirect costs
from productivity losses.
Other health care utilization costs were estimated using a
generalized estimated equation (GEE) model, a logarithmic
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the only predictor variable used in this model.
Model assumptions
No data was available on health related quality of life
(utility) for patients receiving ST. Utilities were therefore
assumed to be equal in the two treatment arms. Hence,
differences in QALYs only resulted from differences in
life expectancy between the two treatment arms. Health
care utilization costs were only available for patients re-
ceiving ERT. We assumed that patients receiving ST in-
curred the same costs as ERT-treated patients with the
exception of treatment costs. Differences in costs there-
fore only resulted from treatment costs and differences
in life expectancy between the two treatment arms.
Analyses
Cost-effectiveness was expressed in incremental cost per
QALY gained and incremental cost per life year gained.
Costs were discounted at a rate of 4% and effects were
discounted at a rate of 1.5% in accordance with Dutch
guidelines for pharmacoeconomic research [22]. A life-
time time horizon was used and a cycle length of ½ year
was used.
Univariate sensitivity analyses were performed to
examine the impact of the assumptions of the model on
the results. We varied the following input variables: ERT
dosage (the registered dose of 20 mg/kg/2 weeks as op-
posed to the mostly used dose in the Netherlands of
40 mg/kg/week in the base case analysis); costs of treat-
ment (€ 11,575.20 per kilo per infusion as opposed to €
23,150.40 per kilo per infusion); time horizon (5 years as
opposed to lifetime in the base case); quality of life (0.49
and 0.74 in both cohorts and 0.31 in the ST cohort com-
bined with 0.62 in the ERT cohort – implying a treat-
ment effect on quality of life – as opposed to 0.62 in
both cohorts); survival in the ERT cohort (varying theFigure 1 Observed and modeled survival curves.distributions used in the parametric survival analyses);
and costs incurred by the ST cohort (double costs and
no costs for the ST-cohort instead of assuming that
‘other healthcare costs’ were the same as the costs seen
in ERT-treated patients).
Next to the univariate sensitivity analyses, probabilistic
sensitivity analyses were performed to examine the
impact of the uncertainty around the values of the
input variables on the estimated effectiveness and cost-
effectiveness of ERT. For this purpose, 1,000 popula-
tions were randomly drawn from relevant distributions
in a Monte Carlo simulation procedure. The results
from the probabilistic sensitivity analyses were presented
in a cost-effectiveness plane (CE-plane). The CE-plane
shows total incremental costs and total incremental effects
of ERT against ST.
Results
Patient characteristics
Estimates for health care utilization costs were based on
data of 12 Dutch classic-infantile patients; 8 male pa-
tients and 4 female patients. At first measurement, aver-
age age of these patients was 3.5 years. Data on quality
of life was available for six patients; four male patients,
average age 6.1 years (range 2.2 – 11.1) at baseline.
Effects
Figure 1 provides observed and modeled survival in both
cohorts. On average, ST-treated patients did not survive
the first half year of life (mean life expectancy 0.40 years),
depicted by the steep decline of the solid black curve in
Figure 1. Life expectancy was considerably longer in the
ERT cohort. The exponential survival function best fitted
the data for ERT-treated patients and is depicted in Figure 1
by the dashed line. The modeled survival followed the ob-
served survival very closely in the first four years. From the
age of 5 years, no deaths were observed in the ERT-group
Table 4 Incremental cost-effectiveness ratios (dosage





Base case analysis dosage
40 mg/kg/week
€ 1,043,868 € 525,873
Registered dosage regimen
(20 mg/kg/2 weeks)
€ 286,114 € 144,137
Lower treatment costs (costs
divided by 2)
€ 549,280 € 276,713
Shorter time horizon (5 years) € 571,701 € 92,634
Lower utility (0.49) in both cohorts € 1,304,835 € 525,873
Higher utility (0.74) in both cohorts € 869,890 € 525,873
Lower utility in ST-treated patients € 1,021,610 € 525,873
Lognormal survival distribution € 1,050,595 € 452,669
No costs incurred by ST-treated patients € 1,049,203 € 528,560
Double cost incurred by ST-treated
patients
€ 1,031,836 € 520,387
Kanters et al. Orphanet Journal of Rare Diseases 2014, 9:75 Page 5 of 8
http://www.ojrd.com/content/9/1/75(solid grey curve) and the observed ERT-curve becomes
flat accordingly. For this period, observed survival is heavily
influenced by a small number of patients with a long
follow-up. The observed and modeled survival curves for
the ERT-group diverge from this point on. Table 3 shows
the results for the total and incremental effects. The life ex-
pectancy in the ERT cohort was estimated to be 13.8 years
(mean QALYs: 7.00). Lifetime incremental QALYs were es-
timated to be 6.75 (7.00 vs. 0.24). Effects were discounted
at a rate of 1.5% per year in both cohorts. For the ERT co-
hort the influence of discounting is larger, as effects occur
over a longer time span, than for the ST cohort.
Costs
Table 3 also shows the total and incremental costs for
classic-infantile patients. The majority of the incremental
costs consisted of drug costs (95% of incremental costs).
In addition, infusion costs were estimated to be € 212,793
(3.0%). ERT-treated patients incurred higher costs than
ST-treated patients not simply because of the ERT treat-
ment they received but also because they lived much lon-
ger. Incremental costs were estimated to be € 7.0 million.
Cost-effectiveness
Table 4 shows the incremental cost-effectiveness ratio
for the treatment of classic-infantile Pompe patients with
ERT. The incremental costs per QALY were estimated to
be € 1.0 million. The incremental cost per life year gained
was estimated to be € 0.5 million.
Sensitivity analyses
Table 4 also provides the results from the sensitivity ana-
lyses. The first sensitivity analysis examined the effect of
dosage on the ICER. Total costs for ERT-treated patients
were considerably lower in the 20 mg/kg/2 weeks ana-
lysis than in the base case analysis, because less medica-
tion was administered. Incremental costs were estimated
to be € 1.9 million. The ICERs at the lower, biweeklyTable 3 Total and incremental costs and effects





0.40 13.79 13.39 [1.55 – 25.23]
QALYs 0.24 7.00 6.75 [2.32 – 11.19]
Total costs € 32,871 € 7,032,899 € 7,000,028 [1,869,635 – 12,130,422]
- ERT costs € - € 6,630,525 € 6,630,525 [1,615,059 – 11,645,991]
- Infusion
costs
€ - € 212,793 € 212,793 [121,477 – 304,108]
- Other
costs
€ 32,871 € 189,582 € 156,711 [131,728 – 181,694]
ST supportive therapy, ERT enzyme replacement therapy, QALY quality
adjusted life year.dose were about 3.6 times lower than the ICER in the
base case analysis.
In a sensitivity analysis, the influence of treatment
costs on the ICER was examined by halving these costs.
The ICER dropped substantially (47%), indicating the
prominent role of treatment costs in the analyses.
When a shorter time horizon of 5 years was used, the
ICER was lower relative to the analyses with a lifetime
horizon. During this period, patients’ body weights’ were
relatively low, which considerably decreased treatment
costs leading to more favorable ICERs. Incremental costs
in this analysis were estimated to be € 1.2 million and
the incremental effects to be 2.20 QALYs.
Since information on utility (quality of life) was lim-
ited, we varied the utility value used in the base-case
analysis by 20% to determine how much it affected the
results (range: 0.49 to 0.74). A change in quality of life
can only affect QALY gain and thereby the ICER; it has
no impact on the incremental costs. A lower value for
quality of life reduced QALY gains and led to an increase
in the ICER. When a higher utility value was used, the
QALY gain increased and the ICER decreased. The use
of a lower utility in the ST-treated patients only (imply-
ing a treatment effect on utility) did not change the
ICER substantially.
Survival in the ERT-treated patients was based on an
exponential survival distribution, because that fitted the
data best. Use of the lognormal distribution, which had
the second lowest BIC, increased life expectancy from
13.8 to 21.9 years, primarily because the predicted survival
later in life was higher. Incremental QALYs increased to
9.3 in this analysis. This longer life expectancy increased
the incremental costs to 9.7 million. However, this did not
affect the ICER, which remained 1.04 million/QALY. Two
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but they did not have any substantial effect on the ICER
(Weibull: life expectancy 14.9 years; ICER 1.05 million/
QALY; log-logistic distribution: life expectancy 20.6 years;
ICER 1.03 million/QALY).
Since no data was available regarding costs of ST treat-
ment we assumed in the base case analysis that these
costs were the same as the costs seen in the ERT-treated
group (excluding ERT-related costs). We tested the im-
portance of this assumption by doubling the costs for the
ST cohort and by setting the total costs in the ST cohort
to zero. However, since the costs for the ST cohort in the
base case analysis were limited because of the short life
expectancy in this group, changes in the costs for the ST
cohort had no appreciable influence on the ICER.
Probabilistic sensitivity analyses
Figure 2 provides the results from the probabilistic sen-
sitivity analyses in a cost-effectiveness plane (CE-plane).
All outcomes of the probabilistic sensitivity analyses are
in the northeast quadrant of the CE-plane, i.e. all draws
resulted in better health outcomes and higher costs.
Furthermore, the CE-plane shows a strong positive asso-
ciation between incremental costs and effects. The CE-
plane further shows that the dispersion of incremental
costs and effects from the average incremental costs and
effects (depicted by the X in the CE-plane) is quite large.
However, the variation of the ICERs is very limited; all
estimates are within a range of €0.85 million/QALY and
€1.15 million/QALY.
Discussion
This is one of the first studies to assess the cost-effec
tiveness of an orphan drug, evaluating the cost-effec
tiveness of enzyme replacement therapy with alglucosi-
dase alfa (Myozyme®) in classic-infantile Pompe disease.
The incremental cost-effectiveness was calculated on theFigure 2 Cost-effectiveness plane: incremental costs and incremental
supportive therapy.basis of available data, a pharmacoeconomic model and
assumptions on disease course. The cost per QALY was
estimated to be € 1.0 million; cost per life year gained
was € 0.5 million.
The results from the univariate sensitivity analyses and
probabilistic sensitivity analyses showed the robustness
of the model. Uncertainty with regard to the ICER is
limited; in all cases the ICER is beyond any convention-
ally used cost-effectiveness threshold. While the absolute
gains in life years, incremental QALYs, and incremental
costs differ between various sensitivity analyses, ICERs
are not affected.
For instance, using log-normal and log-logistic distri-
butions to estimate survival had a large impact on the
life expectancy. This was primarily caused by a higher
survival later in life. However, despite the large gains in
survival, the ICER was relatively unaffected, due to the
significant costs of therapy. This shows the paradoxical
situation of performing an economic evaluation with a
therapy of such high annual costs; better effectiveness
did not lead to a better cost-effectiveness ratio.
This study was performed using currently available in-
formation, but the available evidence on (infantile) Pompe
disease is increasing as the follow-up period increases. For
instance, some patients have already survived to the age of
15 and hope to reach adulthood. Increases in the number
of patients and follow-up time will lead to more stable es-
timates of survival.
Limitations of the study
There are a number of limitations of the study that need
to be stressed. Most limitations are due to the relatively
scarce availability of data, both with respect to number of
patients (due to orphan disease status) and time period
involved.
Firstly, survival estimates from various sources were
combined to increase sample size. Hence, the impliciteffects of enzyme replacement therapy relative to
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were comparable, although the doses used in these groups
of patients varied. The number of patients was too small
to perform subgroup analysis by dosage. Furthermore,
survival was modeled using an exponential survival distri-
bution, which assumes a constant hazard over time. The
choice of the distribution was made on the basis of visual
inspection and best fit of the data [14]. Although a con-
stant hazard might not be a realistic assumption, the sen-
sitivity analyses showed that the choice of the distribution
did not have a large influence on the ICER.
Secondly, the pharmacoeconomic model was based on
observations of a limited period. We assumed that these
results could be extrapolated into the future. Accordingly,
we assumed that patients did not change therapy over the
course of time. In addition, costs and effectiveness of the
treatment were assumed not to change.
A third point of attention concerns the valuation of
health related quality of life, which was assessed using a
proxy version of the EQ-5D. The use of a proxy to make
statements on a subjective measure as quality of life can
be difficult. However, for young children alternatives are
limited [23]. In addition, we only used the utility obser-
vations of children older than two years of age to esti-
mate the utility of the entire group, because of reasons
of applicability of the EQ-5D items. The assumption of
equal utilities in both treatment arms was made due to
these data constraints, and represented a conservative
scenario. Sensitivity analyses showed that the utility level
in the ST-cohort did not influence the results.
Finally, in the current model we used a base case in
which patients received 40 mg/kg/week, since this is the
dosage regimen used by the majority of Dutch patients.
We also used information on patients receiving other dos-
ages (particularly 20 mg/kg/2 weeks) to build the model.
For these patients, treatment costs are lower and effects
are likely to be lower. In the sensitivity analyses, the effect
of dosage on costs was examined, keeping effectiveness
constant. A lower dosage and fewer infusions reduced the
ICER substantially. However, it is likely that a lower dos-
age also leads to a reduction in effects. In that case, the
ICER would increase.
Future research
The current study assesses the cost-effectiveness of ERT
in Pompe disease only in the severe infantile form of the
disease; results may differ for other populations.
A lively debate has taken place in the literature as to
whether or not orphan drugs should be excluded from
any cost-effectiveness assessment [24,25]. The most prom-
inent question is whether society is willing to pay a pre-
mium because of the rarity of a disease. A recent study
showed that this might not be the case, at least in Norway
[26]. In contrast, the Dutch Health Care Insurance Boardseems to place extra value on rarity, judging by the advice
to the Minister of Health to reimburse Myozyme® in in-
fantile Pompe disease in 2012. This decision is probably
also driven by the relatively small budget impact. Other
factors thus play a role in reimbursement decisions. This
hints at the potential role for multi-criteria decision
analyses in reimbursement decisions of orphan drugs,
although deriving weights for the different criteria might
be a major challenge.
Conclusions
In this study, the cost-effectiveness of enzyme replace-
ment therapy with Myozyme® in classic-infantile Pompe
disease was assessed. Incremental costs per QALY were
estimated to be € 1.0 million.
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